Cargando…

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells

BACKGROUND: Triple negative breast cancer (TNBC) is a highly heterogeneous and aggressive type of cancer that lacks effective targeted therapy. Despite detailed molecular profiling, no targeted therapy has been established. Hence, with the aim of gaining deeper understanding of the functional differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gautam, Prson, Karhinen, Leena, Szwajda, Agnieszka, Jha, Sawan Kumar, Yadav, Bhagwan, Aittokallio, Tero, Wennerberg, Krister
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862054/ https://www.ncbi.nlm.nih.gov/pubmed/27165605 http://dx.doi.org/10.1186/s12943-016-0517-3

Ejemplares similares

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
por: Tang, Jing, et al.
Publicado: (2019)

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
por: Gupta, Abhishekh, et al.
Publicado: (2020)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer
por: Wang, Tianduanyi, et al.
Publicado: (2020)

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
por: Jaiswal, Alok, et al.
Publicado: (2017)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Multiobjective optimization identifies cancer-selective combination therapies
por: Pulkkinen, Otto I., et al.
Publicado: (2020)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

Multi‐modal meta‐analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
por: Jaiswal, Alok, et al.
Publicado: (2021)

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples
por: He, Liye, et al.
Publicado: (2015)

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
por: Ali, Mehreen, et al.
Publicado: (2018)

Improved detection of differentially represented DNA barcodes for high‐throughput clonal phenomics
por: Akimov, Yevhen, et al.
Publicado: (2020)

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression
por: Ammad-ud-din, Muhammad, et al.
Publicado: (2017)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

Toward more realistic drug–target interaction predictions
por: Pahikkala, Tapio, et al.
Publicado: (2015)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
por: Julkunen, Heli, et al.
Publicado: (2020)

Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening
por: Duellman, Sarah J., et al.
Publicado: (2015)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
por: Brough, Rachel, et al.
Publicado: (2018)

Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma
por: Benada, Jan, et al.
Publicado: (2023)

Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors
por: Cichonska, Anna, et al.
Publicado: (2017)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
por: Nowsheen, Somaira, et al.
Publicado: (2012)

Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles
por: Tanoli, ZiaurRehman, et al.
Publicado: (2018)

PP2A‐based triple‐strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells
por: Denisova, Oxana V., et al.
Publicado: (2023)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells
por: Denisova, Oxana V., et al.
Publicado: (2022)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
por: Bray, Chandler, et al.
Publicado: (2023)

Overcoming selection bias in synthetic lethality prediction
por: Seale, Colm, et al.
Publicado: (2022)

Machine learning and feature selection for drug response prediction in precision oncology applications
por: Ali, Mehreen, et al.
Publicado: (2018)

Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
por: Deneka, Alexander Y., et al.
Publicado: (2020)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_g1osilkuruvdd7r0he90k1hadh